Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome

Pigment Cell and Melanoma Research

Volumn 28, Issue 1, 2015, Pages 82-93

  Marzese, Diego M ^a   Liu, Michelle ^a   Huynh, Jamie L ^a   Hirose, Hajime ^a   Donovan, Nicholas C ^a   Huynh, Kelly T ^a   Kiyohara, Eiji ^a   Chong, Kelly ^a   Cheng, David ^a   Tanaka, Ryo ^a   Wang, Jinhua ^a   Morton, Donald L ^a   Barkhoudarian, Garni ^a   Kelly, Daniel F ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Alternative splicing; Brain metastasis; CD44v6; Melanoma; Spliceosome

Indexed keywords

CELL SURFACE PROTEIN; HYALURONIC ACID; MONOCLONAL ANTIBODY; SCATTER FACTOR; SMALL INTERFERING RNA; CD44V6 ANTIGEN; ESRP1 PROTEIN, HUMAN; ESRP2 PROTEIN, HUMAN; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; ISOPROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; PTBP1 PROTEIN, HUMAN; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; SPLICING FACTOR U2AF;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER STAGING; CELL MIGRATION; CUTANEOUS MELANOMA; DISEASE COURSE; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; PATIENT; PROTEIN EXPRESSION; RNA SPLICING; SPLICEOSOME; STRATIFICATION; BRAIN TUMOR; CELL MOTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MELANOMA; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; SKIN TUMOR; TUMOR CELL LINE;

ANTIGENS, CD44; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; HYALURONIC ACID; LYMPHATIC METASTASIS; MELANOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NUCLEAR PROTEINS; POLYPYRIMIDINE TRACT-BINDING PROTEIN; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; RIBONUCLEOPROTEINS; RNA, MESSENGER; RNA-BINDING PROTEINS; ROC CURVE; SKIN NEOPLASMS; SPLICEOSOMES;

EID: 84919846591     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12307     Document Type: Article

References (49)

1. Ahrens, T., Sleeman, J.P., Schempp, C.M., Howells, N., Hofmann, M., Ponta, H., Herrlich, P., and Simon, J.C. (2001). Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 20, 3399-3408.
2. Akiyama, H., Barger, S., Barnum, S. et al. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
3. Ananthanarayanan, B., Kim, Y., and Kumar, S. (2011). Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 32, 7913-7923.
4. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C.B., and Seed, B. (1990). CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313.
5. Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
6. Brambilla, R., Couch, Y., and Lambertsen, K.L. (2013). The effect of stroke on immune function. Mol. Cell. Neurosci. 53, 26-33.
7. Bristow, B.N., Casil, J., Sorvillo, F., Basurto-Davila, R., and Kuo, T. (2013). Melanoma-related mortality and productivity losses in the USA, 1990-2008. Melanoma Res. 23, 331-335.
8. Brown, R.L., Reinke, L.M., Damerow, M.S., Perez, D., Chodosh, L.A., Yang, J., and Cheng, C. (2011). CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 121, 1064-1074.
9. Cheng, C., and Sharp, P.A. (2006). Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol. Cell. Biol. 26, 362-370.
10. Choi, S.H., Takahashi, K., Eto, H., Yoon, S.S., and Tanabe, K.K. (2000). CD44s expression in human colon carcinomas influences growth of liver metastases. Int. J. Cancer 85, 523-526.
11. De La Monte, S.M., Moore, G.W., and Hutchins, G.M. (1983). Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43, 3427-3433.
12. Dittmar, K.A., Jiang, P., Park, J.W., Amirikian, K., Wan, J., Shen, S., Xing, Y., and Carstens, R.P. (2012). Genome-wide determination of a broad ESRP-regulated posttranscriptional network by high-throughput sequencing. Mol. Cell. Biol. 32, 1468-1482.
13. Fidler, I.J., Balasubramanian, K., Lin, Q., Kim, S.W., and Kim, S.J. (2010). The brain microenvironment and cancer metastasis. Mol. Cells 30, 93-98.
14. Goodison, S., Urquidi, V., and Tarin, D. (1999). CD44 cell adhesion molecules. Mol. Pathol. 52, 189-196.
15. Gurtner, K., Hessel, F., Eicheler, W., Dorfler, A., Zips, D., Heider, K.H., Krause, M., and Baumann, M. (2012). Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother. Oncol. 102, 444-449.
16. Heid, C.A., Stevens, J., Livak, K.J., and Williams, P.M. (1996). Real time quantitative PCR. Genome Res. 6, 986-994.
17. Hoshimoto, S., Faries, M.B., Morton, D.L. et al. (2012). Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann. Surg. 255, 357-362.
18. Ichikawa, T., Itano, N., Sawai, T., Kimata, K., Koganehira, Y., Saida, T., and Taniguchi, S. (1999). Increased synthesis of hyaluronate enhances motility of human melanoma cells. J. Invest. Dermatol. 113, 935-939.
19. Izraely, S., Sagi-Assif, O., Klein, A. et al. (2012). The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int. J. Cancer 131, 1071-1082.
20. Kagara, N., Huynh, K.T., Kuo, C., Okano, H., Sim, M.S., Elashoff, D., Chong, K., Giuliano, A.E., and Hoon, D.S. (2012). Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am. J. Pathol. 181, 257-267.
21. Koyanagi, K., O'day, S.J., Boasberg, P. et al. (2010). Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res. 16, 2402-2408.
22. Marzese, D.M., Huynh, J.L., Kawas, N.P., and Hoon, D.S.B. (2014a). Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Genomics Data 2, 150-152.
23. Marzese, D.M., Scolyer, R.A., Huynh, J.L. et al. (2014b). Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum. Mol. Genet. 23, 226-238.
24. Marzese, D.M., Scolyer, R.A., Roque, M. et al. (2014c). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology [Epub Ahead of Print].
25. McCourt, M., Wang, J.H., Sookhai, S., and Redmond, H.P. (2001). Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur. J. Surg. Oncol. 27, 396-403.
26. Misra, S., Heldin, P., Hascall, V.C., Karamanos, N.K., Skandalis, S.S., Markwald, R.R., and Ghatak, S. (2011). Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 278, 1429-1443.
27. Mori, T., Martinez, S.R., O'day, S.J. et al. (2006). Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 66, 6692-6698.
28. Nguyen, T., Kuo, C., Nicholl, M. B., Sim, M. S., Turner, R. R., Morton, D. L., and Hoon, D. S. (2011). Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6, 388-394.
29. Oberstrass, F.C., Auweter, S.D., Erat, M. et al. (2005). Structure of PTB bound to RNA: specific binding and implications for splicing regulation. Science 309, 2054-2057.
30. Orian-Rousseau, V. (2010). CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 46, 1271-1277.
31. Orian-Rousseau, V., Chen, L., Sleeman, J.P., Herrlich, P., and Ponta, H. (2002). CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086.
32. Raso-Barnett, L., Banky, B., Barbai, T., Becsagh, P., Timar, J., and Raso, E. (2013). Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression. PLoS ONE 8, e53883.
33. Reinke, L.M., Xu, Y., and Cheng, C. (2012). Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J. Biol. Chem. 287, 36435-36442.
34. Riechelmann, H., Sauter, A., Golze, W., Hanft, G., Schroen, C., Hoermann, K., Erhardt, T., and Gronau, S. (2008). Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 44, 823-829.
35. Saltzman, A.L., Pan, Q., and Blencowe, B.J. (2011). Regulation of alternative splicing by the core spliceosomal machinery. Genes Dev. 25, 373-384.
36. Sampson, J.H., Carter, J.H. Jr, Friedman, A.H., and Seigler, H.F. (1998). Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20.
37. Sato, Y., Goto, Y., Narita, N., and Hoon, D.S. (2009). Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2(Suppl 1), 205-214.
38. Screaton, G.R., Bell, M.V., Jackson, D.G., Cornelis, F.B., Gerth, U., and Bell, J.I. (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl Acad. Sci. USA 89, 12160-12164.
39. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014). Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29.
40. Srikrishna, G., and Freeze, H.H. (2009). Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11, 615-628.
41. Stickeler, E., Fraser, S.D., Honig, A., Chen, A.L., Berget, S.M., and Cooper, T.A. (2001). The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 20, 3821-3830.
42. Sundstrom, T., Daphu, I., Wendelbo, I. et al. (2013). Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res. 73, 2445-2456.
43. Tanemura, A., Terando, A.M., Sim, M.S., Van Hoesel, A.Q., De Maat, M.F., Morton, D.L., and Hoon, D.S. (2009). CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15, 1801-1807.
44. TCGA (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
45. Tijink, B.M., Buter, J., De Bree, R., Giaccone, G., Lang, M.S., Staab, A., Leemans, C.R., and Van Dongen, G.A. (2006). A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res. 12, 6064-6072.
46. Wahl, M.C., Will, C.L., and Luhrmann, R. (2009). The spliceosome: design principles of a dynamic RNP machine. Cell 136, 701-718.
47. Warzecha, C.C., Shen, S., Xing, Y., and Carstens, R.P. (2009). The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol. 6, 546-562.
48. Watermann, D.O., Tang, Y., Zur Hausen, A., Jager, M., Stamm, S., and Stickeler, E. (2006). Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res. 66, 4774-4780.
49. Yae, T., Tsuchihashi, K., Ishimoto, T. et al. (2012). Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun. 3, 883.